These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

335 related articles for article (PubMed ID: 26783311)

  • 21. A Four-Year Experience of Symptomatic Intracranial Hemorrhage Following Intravenous Tissue Plasminogen Activator at a Comprehensive Stroke Center.
    Orlando A; Wagner JC; Fanale CV; Whaley M; McCarthy KL; Bar-Or D
    J Stroke Cerebrovasc Dis; 2016 Apr; 25(4):969-76. PubMed ID: 26856464
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Temporal trends in patient characteristics and treatment with intravenous thrombolysis among acute ischemic stroke patients at Get With The Guidelines-Stroke hospitals.
    Schwamm LH; Ali SF; Reeves MJ; Smith EE; Saver JL; Messe S; Bhatt DL; Grau-Sepulveda MV; Peterson ED; Fonarow GC
    Circ Cardiovasc Qual Outcomes; 2013 Sep; 6(5):543-9. PubMed ID: 24046398
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Cost-effectiveness of thrombolysis within 4.5 hours of acute ischemic stroke: experience from Australian stroke center.
    Tan Tanny SP; Busija L; Liew D; Teo S; Davis SM; Yan B
    Stroke; 2013 Aug; 44(8):2269-74. PubMed ID: 23780955
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Tissue Plasminogen Activator Prescription and Administration Errors within a Regional Stroke System.
    Chung LS; Tkach A; Lingenfelter EM; Dehoney SB; Rollo J; de Havenon A; DeWitt LD; Grantz MR; Wang H; Wold JJ; Hannon PM; Weathered NR; Majersik JJ
    J Stroke Cerebrovasc Dis; 2016 Mar; 25(3):565-71. PubMed ID: 26698642
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Validation of FLAIR hyperintense lesions as imaging biomarkers to predict the outcome of acute stroke after intra-arterial thrombolysis following intravenous tissue plasminogen activator.
    Chung JW; Kim KJ; Noh WY; Jang MS; Yang MH; Han MK; Kwon OK; Jung C; Kim JH; Oh CW; Lee JS; Lee J; Bae HJ
    Cerebrovasc Dis; 2013; 35(5):461-8. PubMed ID: 23735898
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Use of intravenous tissue plasminogen activator and hospital costs for patients with acute ischaemic stroke aged 18-64 years in the USA.
    Joo H; Wang G; George MG
    Stroke Vasc Neurol; 2016 Mar; 1(1):8-15. PubMed ID: 27547449
    [TBL] [Abstract][Full Text] [Related]  

  • 27. The impact of imbalances in baseline stroke severity on outcome in the National Institute of Neurological Disorders and Stroke Recombinant Tissue Plasminogen Activator Stroke Study.
    Kwiatkowski T; Libman R; Tilley BC; Lewandowski C; Grotta JC; Lyden P; Levine SR; Brott T;
    Ann Emerg Med; 2005 Apr; 45(4):377-84. PubMed ID: 15795715
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Acute Ischemic Stroke with Very Early Clinical Improvement: A National Institute of Neurological Disorders and Stroke Recombinant Tissue Plasminogen Activator Stroke Trials Exploratory Analysis.
    Balucani C; Levine SR; Khoury JC; Khatri P; Saver JL; Broderick JP
    J Stroke Cerebrovasc Dis; 2016 Apr; 25(4):894-901. PubMed ID: 26825352
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Intraarterial recombinant tissue plasminogen activator for ischemic stroke: an accelerating dosing regimen.
    Qureshi AI; Suri MF; Shatla AA; Ringer AJ; Fessler RD; Ali Z; Guterman LR; Hopkins LN
    Neurosurgery; 2000 Aug; 47(2):473-6; discussion 477-9. PubMed ID: 10942026
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Predicting major neurological improvement with intravenous recombinant tissue plasminogen activator treatment of stroke.
    Brown DL; Johnston KC; Wagner DP; Haley EC
    Stroke; 2004 Jan; 35(1):147-50. PubMed ID: 14657446
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Intravenous thrombolytic therapy for acute ischemic stroke: the experience of a community hospital.
    Hsu YC; Sung SF; Ong CT; Wu CS; Su YH
    Acta Neurol Taiwan; 2009 Mar; 18(1):14-20. PubMed ID: 19537569
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Cost-effectiveness of tissue plasminogen activator for acute ischemic stroke. NINDS rt-PA Stroke Study Group.
    Fagan SC; Morgenstern LB; Petitta A; Ward RE; Tilley BC; Marler JR; Levine SR; Broderick JP; Kwiatkowski TG; Frankel M; Brott TG; Walker MD
    Neurology; 1998 Apr; 50(4):883-90. PubMed ID: 9566367
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Preclusion of ischemic stroke patients from intravenous tissue plasminogen activator treatment for mild symptoms should not be based on low National Institutes of Health Stroke Scale Scores.
    Wendt M; Tütüncü S; Fiebach JB; Scheitz JF; Audebert HJ; Nolte CH
    J Stroke Cerebrovasc Dis; 2013 May; 22(4):550-3. PubMed ID: 23433783
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Rehabilitation outcomes of stroke patients treated with tissue plasminogen activator.
    Meiner Z; Sajin A; Schwartz I; Tsenter J; Yovchev I; Eichel R; Ben-Hur T; Leker RR
    PM R; 2010 Aug; 2(8):698-702; quiz 792. PubMed ID: 20709299
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Tissue plasminogen activator thrombolytic therapy for acute ischemic stroke in 4 hospital groups in Japan.
    Kono S; Deguchi K; Morimoto N; Kurata T; Deguchi S; Yamashita T; Ikeda Y; Matsuura T; Narai H; Omori N; Manabe Y; Yunoki T; Takao Y; Kawata S; Kashihara K; Abe K
    J Stroke Cerebrovasc Dis; 2013 Apr; 22(3):190-6. PubMed ID: 21968092
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Risks of intracranial hemorrhage among patients with acute ischemic stroke receiving warfarin and treated with intravenous tissue plasminogen activator.
    Xian Y; Liang L; Smith EE; Schwamm LH; Reeves MJ; Olson DM; Hernandez AF; Fonarow GC; Peterson ED
    JAMA; 2012 Jun; 307(24):2600-8. PubMed ID: 22735429
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Outcomes following telestroke-assisted thrombolysis for stroke in Ontario, Canada.
    Porter J; Hall RE; Kapral MK; Fang J; Khan F; Silver FL
    J Telemed Telecare; 2018 Aug; 24(7):492-499. PubMed ID: 28691864
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Effects of tissue plasminogen activator for acute ischemic stroke at one year. National Institute of Neurological Disorders and Stroke Recombinant Tissue Plasminogen Activator Stroke Study Group.
    Kwiatkowski TG; Libman RB; Frankel M; Tilley BC; Morgenstern LB; Lu M; Broderick JP; Lewandowski CA; Marler JR; Levine SR; Brott T
    N Engl J Med; 1999 Jun; 340(23):1781-7. PubMed ID: 10362821
    [TBL] [Abstract][Full Text] [Related]  

  • 39. The iScore predicts effectiveness of thrombolytic therapy for acute ischemic stroke.
    Saposnik G; Fang J; Kapral MK; Tu JV; Mamdani M; Austin P; Johnston SC; ;
    Stroke; 2012 May; 43(5):1315-22. PubMed ID: 22308252
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Association of geographical factors with administration of tissue plasminogen activator for acute ischemic stroke.
    Kunisawa S; Morishima T; Ukawa N; Ikai H; Otsubo T; Ishikawa KB; Yokota C; Minematsu K; Fushimi K; Imanaka Y
    J Am Heart Assoc; 2013 Sep; 2(5):e000336. PubMed ID: 24045119
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 17.